2022 Development Timelines
1AD - 2022 Goals
Significantprogress anticipated on both existing core programs and further pipelineexpansion
AD-214 – First in class anti-fibrotic
• Inhaledformulation development: nebulisation feasibility, efficacy in animal model ofIPF (Q1); lung distribution imaging in healthy and disease model animals (Q1);dose finding and clinical formulation (Q2)
• Intravenousformulation development (Q3)
• GLP toxicologywith inhaled formulation (commences 2H22)
• Continuing partneringdiscussions (Q1); selection of next indication
GE Healthcare – GZMB PET imaging
• Pre-clinicalproof of concept – milestone payment (mid-22)
Carina Biotech – i-body enabled CAR-T cells
• 1stexperimental results on Target #1
• Commencei-body discovery on Target #2
Internal pipeline and platform development
• Initialfunctional data on i-body binders against internal Target #2 (2H22)
• i-body2.0: newintellectual property filed (end’22)
• 7 programs inpipeline (end’22)
• Additionalpatent filings, grants on individual i-body enabled products
- Forums
- ASX - By Stock
- 1AD
- 1AD 2022 Development Timelines
1AD 2022 Development Timelines
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.51M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 52630 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 169872 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 52630 | 0.019 |
8 | 812053 | 0.018 |
1 | 1000000 | 0.017 |
2 | 312561 | 0.016 |
2 | 190999 | 0.011 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 169872 | 1 |
0.021 | 555555 | 1 |
0.022 | 810000 | 2 |
0.023 | 17643 | 1 |
0.024 | 425050 | 3 |
Last trade - 16.12pm 13/09/2024 (20 minute delay) ? |
Featured News
1AD (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online